Advertisement

Topics

Amgen Passes Key Trial With “Son of Dmab” For Osteoporosis

09:45 EDT 21 Apr 2011 |

The financial crowd who follows Amgen may be talking all about dividends or techniques to boost the stock through share buybacks, but the medical and scientific world will be chirping today about an interesting new finding the company has made for treating osteoporosis. Amgen (NASDAQ: AMGN), the Thousand Oaks, CA, biotech giant with R&D operations [...]

Original Article: Amgen Passes Key Trial With “Son of Dmab” For Osteoporosis

NEXT ARTICLE

More From BioPortfolio on "Amgen Passes Key Trial With “Son of Dmab” For Osteoporosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...